TS
FLXN

Thomas Steyer’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Thomas Steyer’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-50,000
Closed -$823K – 112
2014
Q1 		$823K Buy
+50,000
New +$864K 0.02% 83

Other funds holding FLXN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Thomas Steyer's FLXN Position: Q2 2014 in Review

Thomas Steyer sold out of Flexion Therapeutics, Inc. (FLXN) in Q2 2014, closing a stake of 50,000 shares — an estimated $823K sold.

Thomas Steyer first reported a position in FLXN in Q1 2014 and held it in 1 quarter. The position peaked at $823K in Q1 2014. 42 funds tracked by Wall St. Rank hold FLXN as of Q2 2014.

  • Thomas Steyer reported no remaining Flexion Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Thomas Steyer sold 50,000 Flexion Therapeutics, Inc. shares in Q2 2014, an estimated $823K.
  • Thomas Steyer first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 1 quarter.
  • Thomas Steyer's Flexion Therapeutics, Inc. position peaked at $823K in Q1 2014.
  • 42 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q2 2014.

Based on Farallon Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.